Morbid Obesity
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Morbid Obesity is a moderately active landscape with 53 programs across 27 companies. The most active players are AstraZeneca, Merck & Co., Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 21 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
AstraZeneca
2 programs
Merck & Co.
2 programs
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2 programs
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
Viking Therapeutics, Inc.
1 program
Milestone Pharmaceuticals Inc.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
91%
Small molecule
52 of 57 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 57 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.
Analysis
Trial Status
16
clinical trials
Clinical Trials
Trial Activity
16 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)